GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma A/S (STU:A71) » Definitions » Cyclically Adjusted PS Ratio

Ascendis Pharma A/S (STU:A71) Cyclically Adjusted PS Ratio : 128.87 (As of Jun. 10, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Ascendis Pharma A/S Cyclically Adjusted PS Ratio?

As of today (2024-06-10), Ascendis Pharma A/S's current share price is €125.00. Ascendis Pharma A/S's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €0.97. Ascendis Pharma A/S's Cyclically Adjusted PS Ratio for today is 128.87.

The historical rank and industry rank for Ascendis Pharma A/S's Cyclically Adjusted PS Ratio or its related term are showing as below:

STU:A71' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 111.05   Med: 135.8   Max: 170.19
Current: 125.58

During the past years, Ascendis Pharma A/S's highest Cyclically Adjusted PS Ratio was 170.19. The lowest was 111.05. And the median was 135.80.

STU:A71's Cyclically Adjusted PS Ratio is ranked worse than
96.61% of 502 companies
in the Biotechnology industry
Industry Median: 5.43 vs STU:A71: 125.58

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Ascendis Pharma A/S's adjusted revenue per share data for the three months ended in Mar. 2024 was €1.686. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €0.97 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Ascendis Pharma A/S Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Ascendis Pharma A/S's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascendis Pharma A/S Cyclically Adjusted PS Ratio Chart

Ascendis Pharma A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 131.76

Ascendis Pharma A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 171.34 127.74 120.33 131.76 138.39

Competitive Comparison of Ascendis Pharma A/S's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Ascendis Pharma A/S's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma A/S's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma A/S's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma A/S's Cyclically Adjusted PS Ratio falls into.



Ascendis Pharma A/S Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Ascendis Pharma A/S's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=125.00/0.97
=128.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma A/S's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Ascendis Pharma A/S's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.686/118.4000*118.4000
=1.686

Current CPI (Mar. 2024) = 118.4000.

Ascendis Pharma A/S Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.362 99.700 0.430
201409 0.192 99.700 0.228
201412 0.167 99.400 0.199
201503 0.085 100.200 0.100
201506 0.081 100.300 0.096
201509 0.086 100.200 0.102
201512 0.079 99.800 0.094
201603 0.050 100.200 0.059
201606 0.045 100.600 0.053
201609 0.046 100.200 0.054
201612 0.034 100.300 0.040
201703 0.011 101.200 0.013
201706 0.014 101.200 0.016
201709 0.013 101.800 0.015
201712 0.008 101.300 0.009
201803 0.001 101.700 0.001
201806 0.000 102.300 0.000
201809 0.000 102.400 0.000
201812 0.250 102.100 0.290
201903 0.125 102.900 0.144
201906 0.068 102.900 0.078
201909 0.047 102.900 0.054
201912 0.052 102.900 0.060
202003 0.046 103.300 0.053
202006 0.030 103.200 0.034
202009 0.052 103.500 0.059
202012 0.010 103.400 0.011
202103 0.014 104.300 0.016
202106 0.019 105.000 0.021
202109 0.020 105.800 0.022
202112 0.086 106.600 0.096
202203 0.120 109.900 0.129
202206 0.110 113.600 0.115
202209 0.274 116.400 0.279
202212 0.409 115.900 0.418
202303 0.599 117.300 0.605
202306 0.843 116.400 0.857
202309 0.854 117.400 0.861
202312 2.434 116.700 2.469
202403 1.686 118.400 1.686

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ascendis Pharma A/S  (STU:A71) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Ascendis Pharma A/S Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Ascendis Pharma A/S's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascendis Pharma A/S (STU:A71) Business Description

Traded in Other Exchanges
Address
Tuborg Boulevard 12, Hellerup, DNK, DK-2900
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.

Ascendis Pharma A/S (STU:A71) Headlines

No Headlines